Regional Account Manager (Northwest)

Organization
Regional Account Manager (Northwest)
Job Location
530 Fairview Ave N
Seattle, WA 98109
Benefits

Competitive

Job Description

The Regional Account Manager (RAM) will be accountable for revenue generation across the greater Pacific Northwest by selling directly to customers primarily via face-to-face contact.

Responsibilities:
•Sell the nCounter Analysis System and associated consumables to support bioscience and medical research as well as diagnostics instrumentation.
•Work very closely with their Field Applications and Inside Sales colleagues, as well as Management, to leverage and develop key customer relationships.
•Responsible for devising direct sales plans and strategies. Duties may require a high level of travel

Requirements

•Requires a minimum of a bachelor's degree in a related science and may have an advanced degree, certification or additional professional training. Typically requires 6 years of relevant experience (3+ years in direct sales).
•Requires knowledge and understanding of Gene Expression analysis, miRNA and Copy Number Variation assays. NGS workflow and application knowledge preferred. Ability to understand protein analysis workflows.
•Requires excellent communication skills, Verbal and written. Ability to conduct technical presentations.
•Ability to travel up to 75%.
•Strong working knowledge of the sales process (quoting, purchasing, revenue recognition) as well as a good understanding of the Miller Heiman selling process and terminology.

About Our Organization

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications.

NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer.

Organizations performing cancer research, biomarker validation and screening, and next-generation sequencing validation are rapidly adopting the nCounter® Analysis System. By providing simple, multiplexed digital profiling of single molecules, the NanoString platform represents a natural, digital downstream companion to next-generation sequencing and enables researchers to embark on studies that were previously inconceivable.

Leading researchers and institutions are finding that NanoString's nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues.

In addition to continuing to extend the applications for the nCounter system in the discovery, target validation and routine testing segments of the genomics research market, the company's goal is to become the platform of choice for diagnostic testing based on multiplexed gene signatures that can be offered in hospitals and pathology laboratories worldwide, following appropriate regulatory approvals. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics.

New study finds bias against female lecturers among student course evaluations, the Economist reports.

A research duo finds that science and technology graduate students who turn away from academic careers do so because of changes in their own interests.

Students whose classmates are interested in science are more likely to think about a career in science, technology, engineering, and mathematics, a new study says.

CNBC reports that the genetic counseling field is expected to grow as personalized medicine becomes more common.